Tvardi Therapeutics (TVRD) Competitors $28.05 +1.40 (+5.25%) As of 08/22/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock TVRD vs. IOVA, AKBA, AVXL, QURE, IMNM, SANA, NRIX, ATAI, GYRE, and PHARShould you be buying Tvardi Therapeutics stock or one of its competitors? The main competitors of Tvardi Therapeutics include Iovance Biotherapeutics (IOVA), Akebia Therapeutics (AKBA), Anavex Life Sciences (AVXL), uniQure (QURE), Immunome (IMNM), Sana Biotechnology (SANA), Nurix Therapeutics (NRIX), atai Life Sciences (ATAI), Gyre Therapeutics (GYRE), and Pharming Group (PHAR). These companies are all part of the "pharmaceutical products" industry. Tvardi Therapeutics vs. Its Competitors Iovance Biotherapeutics Akebia Therapeutics Anavex Life Sciences uniQure Immunome Sana Biotechnology Nurix Therapeutics atai Life Sciences Gyre Therapeutics Pharming Group Iovance Biotherapeutics (NASDAQ:IOVA) and Tvardi Therapeutics (NASDAQ:TVRD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Do insiders & institutionals believe in IOVA or TVRD? 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 44.7% of Tvardi Therapeutics shares are owned by institutional investors. 10.3% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 3.1% of Tvardi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more risk & volatility, IOVA or TVRD? Iovance Biotherapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Do analysts rate IOVA or TVRD? Iovance Biotherapeutics presently has a consensus price target of $11.90, indicating a potential upside of 342.38%. Tvardi Therapeutics has a consensus price target of $64.25, indicating a potential upside of 129.06%. Given Iovance Biotherapeutics' higher probable upside, equities research analysts plainly believe Iovance Biotherapeutics is more favorable than Tvardi Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Iovance Biotherapeutics 1 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.36Tvardi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IOVA or TVRD more profitable? Iovance Biotherapeutics has a net margin of -161.44% compared to Tvardi Therapeutics' net margin of -595.39%. Iovance Biotherapeutics' return on equity of -52.87% beat Tvardi Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Iovance Biotherapeutics-161.44% -52.87% -41.31% Tvardi Therapeutics -595.39%-565.83%-66.71% Does the media prefer IOVA or TVRD? In the previous week, Iovance Biotherapeutics had 18 more articles in the media than Tvardi Therapeutics. MarketBeat recorded 19 mentions for Iovance Biotherapeutics and 1 mentions for Tvardi Therapeutics. Iovance Biotherapeutics' average media sentiment score of 0.71 beat Tvardi Therapeutics' score of -0.26 indicating that Iovance Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 6 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Tvardi Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher valuation & earnings, IOVA or TVRD? Tvardi Therapeutics has lower revenue, but higher earnings than Iovance Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIovance Biotherapeutics$164.07M5.93-$372.18M-$1.23-2.19Tvardi Therapeutics$7.14M36.85-$70.87MN/AN/A SummaryIovance Biotherapeutics beats Tvardi Therapeutics on 11 of the 14 factors compared between the two stocks. Get Tvardi Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TVRD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TVRD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TVRD vs. The Competition Export to ExcelMetricTvardi TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$263.04M$3.12B$5.83B$9.78BDividend YieldN/A2.23%4.40%4.05%P/E RatioN/A21.0031.3026.05Price / Sales36.85357.30455.25117.77Price / CashN/A44.5038.0259.36Price / Book7.998.129.536.60Net Income-$70.87M-$54.72M$3.26B$265.65M7 Day Performance16.88%2.62%2.14%2.01%1 Month Performance-2.06%2.68%2.81%-0.33%1 Year PerformanceN/A10.93%30.70%19.04% Tvardi Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TVRDTvardi Therapeutics1.3062 of 5 stars$28.05+5.3%$64.25+129.1%N/A$263.04M$7.14M0.0080News CoverageIOVAIovance Biotherapeutics4.8085 of 5 stars$2.55+4.1%$11.90+366.7%-76.9%$886.54M$241.53M-2.07500Analyst ForecastShort Interest ↓AKBAAkebia Therapeutics3.9393 of 5 stars$3.25-1.2%$6.75+107.7%+117.0%$872.33M$203.73M-19.12430Analyst RevisionAVXLAnavex Life Sciences3.7652 of 5 stars$9.94-1.7%$44.00+342.7%+55.5%$868.39MN/A-17.4440Analyst ForecastQUREuniQure2.4671 of 5 stars$16.18+2.5%$37.45+131.5%+141.4%$865.80M$27.12M-4.13500Analyst RevisionIMNMImmunome1.8164 of 5 stars$10.28+3.4%$23.14+125.1%-29.4%$865.23M$9.04M-3.3440News CoverageAnalyst ForecastGap UpSANASana Biotechnology2.9653 of 5 stars$3.33-2.9%$8.00+140.2%-37.3%$815.68MN/A-3.14380NRIXNurix Therapeutics2.6341 of 5 stars$10.58+0.2%$28.87+172.8%-56.1%$807.30M$54.55M-4.05300ATAIatai Life Sciences3.6027 of 5 stars$3.88-3.2%$11.25+189.9%+254.3%$803.35M$310K-5.6280Analyst DowngradeAnalyst RevisionGap UpGYREGyre Therapeutics0.0659 of 5 stars$8.14-1.0%N/A-28.7%$791.69M$102.19M814.8140Gap UpPHARPharming Group2.3819 of 5 stars$11.65+2.4%$30.00+157.5%+72.3%$779.70M$297.20M-89.62280Gap Up Related Companies and Tools Related Companies Iovance Biotherapeutics Alternatives Akebia Therapeutics Alternatives Anavex Life Sciences Alternatives uniQure Alternatives Immunome Alternatives Sana Biotechnology Alternatives Nurix Therapeutics Alternatives atai Life Sciences Alternatives Gyre Therapeutics Alternatives Pharming Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TVRD) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tvardi Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tvardi Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access